View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Greenyard NV: 1 director

A director at Greenyard NV bought 27,914,598 shares at 7.400EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Alfen: Preview - muddling through? Belgian telcos: Competition Authority investigation on Proximus/Orange Belgium MoU. Brunel International: 2Q25 below, 3Q25 outlook cut, cost savings protect FY25 estimates. Euronext: Another record set of results. Fugro: Sharper V-shape? GBL: Weak NAV performance, as expected. KBC Ancora: Cooperative CERA increasing its stake to 51.24%, using excess cash. UCB: Renewed US threats to cut drug prices. Umicore: 1H25 and guide broadly in-line, new S...

Jacob Mekhael
  • Jacob Mekhael

Sequana Medical Publishes alfapump case report in journal, US launch o...

Sequana announced the publication of a case report of a patient in the POSEIDON study that underwent a successful robotic hernia repair following control of their ascites with the alfapump. Looking ahead, the US commercial launch remains on track for this quarter. Should the company demonstrate initial commercial traction during the soft launch phase, this could trigger additional investor interest to fund the company into the broader launch, which is expected in 2Q26. We reiterate our € 5 TP an...

Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Morning Notes : ARCAD NA, ENX FP, FUR NA, GBLB BB, QFG BB, SEQUA BB, U...

: ARCAD NA, ENX FP, FUR NA, GBLB BB, QFG BB, SEQUA BB, UMI BB, XFAB FP

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

UCB - Still Plenty of Upside – PT up to €270 (BUY, TP €270 [250], 8pgs...

We upgrade our 2026 Bimzelx sales to be €0.9bn higher than consensus with conservative assumptions & and are now 11% above consensus on 2026 group sales & 19% on EBITDA. We upgrade our already above-consensus ‘27 EBITDA by 5%. Using our proprietary product-by-product Contribution Analysis, we show that the gross margin is highly sensitive to Bimzelx growth. We analyse the galvokimig data, which looks very strong Vs Dupi. Whilst UCB pipeline readouts & Moonlake risk will dominate specialists’ tho...

Jacob Mekhael
  • Jacob Mekhael

UCB 1H25 conference call feedback

UCB reported 1H25 results this morning with a clear beat on CSS. In this note we summarise our key takeaways from the conference call with management.

Louis Boujard ... (+4)
  • Louis Boujard
  • CFA
  • Philippe Ourpatian
  • Thomas Zlowodzki
Louis Boujard ... (+3)
  • Louis Boujard
  • CFA
  • Philippe Ourpatian
Stefano Toffano
  • Stefano Toffano
Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
Jacob Mekhael
  • Jacob Mekhael

UCB 1H25 earnings beat driven by Bimzelx, raises FY25 guidance

UCB's growth continues with 1H25 earnings increasing to € 3.49b, beating CSS expectations by approx. 8%. We note that Bimzelx performed significantly higher vs. expectations bringing in € 799m (CSS: € 615m) continuing its solid growth momentum. The company updated its FY25 guidance to revenue of at least € 7b based on a strong outlook for the remainder of the year. We reiterate our €214 TP and Accumulate.

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

AB InBev: 2Q25 results. Air France-KLM: Nice beat, let's see how FY25 finishes. AMG: Uptrend continues in 2Q25 with 23% EBITDA beat and guidance up to +US$200m. Aperam: Slight 2Q25 EBITDA beat, 3Q25 seen down QoQ. Arcadis: EBITA margin held up well in 2Q25, order intake mixed. Ayvens: 2Q25 results. Azelis: Soft but largely in-line 2Q25 with EMEA offsetting weaker APAC. Bekaert: 1H25 miss and lowered outlook to result in c.5% consensus downside. Corbion: Taking it to the wire. dsm...

Hilde Van Boxstael ... (+7)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Morning Notes : ABI BB, ARGX BB, BEKB BB, CRBN NA, DSFIR NA, ENX FP, F...

: ABI BB, ARGX BB, BEKB BB, CRBN NA, DSFIR NA, ENX FP, FAGR BB, FLOW NA, INGA NA, ONTEX BB, UCB BB, AZE BB, SYENS BB

Hilde Van Boxstael ... (+7)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Thibault Leneeuw
  • Wim Hoste
  • Wim Lewi
Thibault Leneeuw
  • Thibault Leneeuw

Azelis Weak results are anticipated, limited downside risk

Since our last update, the market has experienced a wave of profit warnings and significant FX volatility. As a result, we find it necessary to revise our estimates. We are lowering our adjusted EBITA forecast from €471m to €451m, primarily due to adverse FX movements. Furthermore, we decrease our GPm expectations for the Americas. We anticipated that improvements in the F&F segment would support margin expansion in 2Q25, the combination of FX headwinds, macroeconomic uncertainty, and unfavourab...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch